ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2181

Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients

Valeria Manfrè1, Salvatore Parisi2, Isabella Caligiuri2, Ombretta Repetto3, Alen Zabotti1, Enrico Pegolo4, Cinzia Fabro1, Salvatore De Vita1, Vincenzo Canzonieri2, Carla Di Loreto4, Flavio Rizzolio2 and Luca Quartuccio1, 1Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 2Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy, 3Facility of Bio-Proteomics, Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy, 4Institute of Pathology, Azienda Sanitaria Universitaria Friuli Centrale c/o Università degli studi di Udine, Udine, Italy

Meeting: ACR Convergence 2023

Keywords: Sjögren's syndrome, Tissue Engineering

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In primary Sjögren’s syndrome (pSS), salivary epithelial cells show an active role in the initiation and reiteration of the immunomediated damage. Epithelial saliva production is regulated by autonomic stimuli, intracellular calcium and cAMP concentration. The latter controls the action of cystic fibrosis transmembrane conductance regulator (CFTR), whose malfunction is postulated in sicca syndrome and pSS pathogenesis. (1) Forskolin is an activator of CFTR used in organoid swelling test in human salivary-gland derived organoid culture systems. Interestingly, also PDE4 is involved in intracellular cAMP deregulation: PDE4 inhibition might thus stimulate salivary function in pSS. (2-3) To the best of our knowledge, no data on the application of human salivary gland organoids specifically for testing drugs effective on xerostomia in pSS are found in literature. The objectives of this study are: to culture vital salivary gland organoids obtained through labial or parotid biopsy of pSS patients; to evaluate the morphological structure and functional capacity of organoids in basal condition and after stimulation with forskolin and PDE4 inhibitor apremilast.

Methods: Salivary gland tissues were harvested from 5 pSS patients through labial or parotid biopsy. After tissue processation and vital organoids obtainment, swelling essay and cell proliferation tests were performed after forskolin and apremilast application, compared to DMSO-treated controls. Immunohistochemistry evaluation on original salivary gland tissue and corresponding organoids was performed, by testing: alpha-amylase and AQP5 for acinar differentiation; EMA for ductal differentiation; calponin for myoepithelial differentiation and CK5 for basal differentiation; CK14, cKit and CD34 as markers of progenitor/stem cells.

Results: After application of forskolin or apremilast, we observed organoid swelling after 30 minutes, compatible with positive functional status and enhancement of saliva production. DMSO-treated controls were instead unaffected. In 3 cases apremilast induced proliferation of the organoids (Fig.1). All the cases were positive for CK14, most of the cases for CK5. All the cases were positive for amylase; its secretion, and thus functional status of organoids, was confirmed by its high concentration in the culture medium. A focal ductal differentiation was found in some cases, highlighted by EMA positivity. The more differentiated EMA positive areas were negative for the staminal marker CK14, showing a sort of “complementary staining” (Fig.2).

Conclusion: Our data confirm that, from pSS epithelium, differentiated cells that escape senescence and vital and functional organoids that recapitulate the development of original salivary glands can be obtained from different target tissues of pSS. The direct stimulating effect of PDE4 inhibitor apremilast on pSS human salivary gland organoids is reported, opening new perspectives on targeting oral dryness with drugs that combine secretagogue and immunomodulatory effects.

References:
(1) Zeng M et al. Gastroenterology, 2017
(2) Boyd A et al. Biochem J, 2021
(3) Yoshimoto S et al. Dis Model Mech, 2020

Supporting image 1


Disclosures: V. Manfrè: None; S. Parisi: None; I. Caligiuri: None; O. Repetto: None; A. Zabotti: AbbVie/Abbott, 6, 12, Paid Instructor, Amgen, 6, Eli Lilly, 6, Janssen, 6, Novartis, 6, 12, Paid Instructor, UCB, 6, 12, Paid Instructor; E. Pegolo: None; C. Fabro: None; S. De Vita: None; V. Canzonieri: None; C. Di Loreto: None; F. Rizzolio: None; L. Quartuccio: None.

To cite this abstract in AMA style:

Manfrè V, Parisi S, Caligiuri I, Repetto O, Zabotti A, Pegolo E, Fabro C, De Vita S, Canzonieri V, Di Loreto C, Rizzolio F, Quartuccio L. Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/secretagogue-effect-of-pde4-inhibitor-apremilast-on-human-salivary-gland-organoids-obtained-from-primary-sjogrens-syndrome-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secretagogue-effect-of-pde4-inhibitor-apremilast-on-human-salivary-gland-organoids-obtained-from-primary-sjogrens-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology